Two Drug Interaction Studies of Sirolimus in Combination with Sorafenib or Sunitinib in Patients with Advanced Malignancies

PURPOSE: Sirolimus is the prototypical mammalian target of rapamycin inhibitor. Sorafenib and sunitinib are small molecule inhibitors of multiple kinases including vascular endothelial receptor kinases (VEGFR). These agents have different mechanisms of action providing a strong rationale for combina...

Descrición completa

Gardado en:
Detalles Bibliográficos
Main Authors: Gangadhar, Tara C., Cohen, Ezra E. W., Wu, Kehua, Janisch, Linda, Geary, David, Kocherginsky, Masha, House, Larry K., Ramirez, Jackie, Undevia, Samir D., Maitland, Michael L., Fleming, Gini F., Ratain, Mark J.
Formato: Artigo
Idioma:Inglês
Publicado: 2011
Assuntos:
Article
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC3077032/
https://ncbi.nlm.nih.gov/pubmed/21447721
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-10-2061
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares